Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 20 Other hematologic neoplasm 1 Lymphoid 1

Conditions

Natural Killer/T-cell Lymphoma 1

Interventions

Cyclophosphamide 166 Rituximab 153 Specimen Handling 111 Biopsy 89 Magnetic Resonance Spectroscopy 87 Vincristine 85 Doxorubicin 79 Prednisone 78 fludarabine 68 venetoclax 65 obinutuzumab 60 ibrutinib 54 Lenalidomide 53 Dexamethasone 53 Cytarabine 47 Methotrexate 44 acalabrutinib 42 Etoposide 41 CT-P10 39 blinatumomab 38 Bendamustine Hydrochloride 34 fludarabine phosphate 33 prednylidene 32 Gemcitabine 32 deltacortene 31 Calcium Dobesilate 30 zanubrutinib 29 pembrolizumab 29 glofitamab 27 Nivolumab 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

isatuximab × Lymphoid × 90 days × Clear all

NCT04763616 2026-04-27

ICING

Samsung Medical Center

Phase 2 Completed

Natural Killer/T-cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡